SONM Sonim Technologies Inc - 8-K

Item
1.02

Termination
of a Material Definitive Agreement.

As
previously disclosed, on September 29, 2025, DNA X, Inc. (the “Company”) and Chardan Capital Markets LLC (“Chardan”)
entered into a ChEF Purchase Agreement (the “ChEF Agreement”) pursuant to which Chardan committed to purchase, subject to
certain limitations and conditions set forth in the ChEF Agreement, up to $500 million of shares of the Company’s common stock,
par value $0.001 per share, and a Registration Rights Agreement (the “Registration Rights Agreement”) providing Chardan with
certain registration rights with respect the shares of common stock purchasable under the ChEF Agreement.

On
May 29, 2026, the Company and Chardan entered into a letter agreement pursuant
to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement
and Registration Rights Agreement.

The
foregoing descriptions of the ChEF Agreement and Registration
Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text thereof, copies of which
were filed
as Exhibits 10.1 and 10.2 to
the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on September
29, 2025.

Item
9.01

Financial
Statements and Exhibits.

(d)

Exhibits

Exhibit
Number

Description

104

Cover
Page Interactive Data File (embedded within the Inline XBRL document)